ArticleCell host & microbe2021
A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses.
Abstract read
In one paragraph
Article in Cell host & microbe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
134 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mucosal immune response in biology, disease prevention and treatment.Signal transduction and targeted therapy · 2025Pooled it
- Impact of an aerosolized or intramuscular adenovirus type 5-vectored COVID-19 vaccine on Fc-mediated immune effector functions in a hybrid immunity population.Frontiers in immunology · 2025Trial
- Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children.JCI insight · 2022Trial
- Building better antibody responses: The interplay of infection, vaccination, and immune imprinting.PNAS nexus · 2026Review
- Non-neutralizing antibodies against SARS-CoV-2 nucleocapsid protein mediate variant transcendent antibody-dependent cellular cytotoxicity.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants.Journal of virology · 2025Article
- Extensive cross-reactive T cell epitopes across SARS-CoV-2 Omicron variant spikes with finite immune evasion mutations.Journal of translational medicine · 2025Article
- Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates.NPJ vaccines · 2025Article
- Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Multi-layered deep immune profiling, SARS-CoV-2 RNAemia and inflammation in unvaccinated COVID-19 individuals with persistent symptoms.Communications medicine · 2025Article
- Longitudinal humoral immunity against SARS-CoV-2 Spike following infection in individuals from Cameroon.Virology · 2025Article
- Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice.Nature communications · 2025Article
- Viral glycoprotein-mediated entry and antibody-mediated immunity in HIV-1 and SARS-CoV-2 infection.Frontiers in immunology · 2025Review
- A longitudinal assessment of the antibody response to SARS-CoV-2 infection in the New Mexican population.PloS one · 2025Article
- Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses.PLoS pathogens · 2024Article
- Review
- Review
- Article
- Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions.PLoS pathogens · 2024Article
- Intra-Host Evolution Analyses in an Immunosuppressed Patient Supports SARS-CoV-2 Viral Reservoir Hypothesis.Viruses · 2024Article
74 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
35 authors.
Alexandra TauzinCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Manon NayracCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Mehdi BenlarbiCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Shang Yu GongCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2BA, Canada.
Romain GasserCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Guillaume Beaudoin-BussièresCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Nathalie BrassardCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Annemarie LaumaeaCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Dani VézinaCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Jérémie PrévostCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Sai Priya AnandCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2BA, Canada.
Catherine BourassaCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Gabrielle Gendron-LepageCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Halima MedjahedCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Guillaume GoyetteCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Julia NiesslCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada; Consortium for HIV/AIDS Vaccine Development (CHAVD), La Jolla, CA, USA.
Olivier TastetCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Laurie GokoolCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Chantal MorrisseauCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Pascale ArlottoCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Leonidas StamatatosFred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA 98109, USA; University of Washington, Department of Global Health, Seattle, WA 98109, USA.
Andrew T McGuireFred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA 98109, USA.
Catherine LarochelleCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département des Neurosciences, Université de Montréal, Montreal, QC H3C 3J7, Canada.
Pradeep UchilDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06510, USA.
Maolin LuDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06510, USA.
Walther MothesDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06510, USA.
Gaston De SerresInstitut National de Santé Publique du Québec, Quebec, QC, H2P 1E2, Canada.
Sandrine MoreiraLaboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
Michel RogerCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada; Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
Jonathan RichardCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Valérie Martel-LaferrièreCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Ralf DuerrDepartment of Microbiology, New York University School of Medicine, New York, NY 10016, USA.
Cécile TremblayCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada. Electronic address: c.tremblay@umontreal.ca.
Daniel E KaufmannCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Médecine, Université de Montréal, Montreal, QC H3T 1J4, Canada; Consortium for HIV/AIDS Vaccine Development (CHAVD), La Jolla, CA, USA. Electronic address: daniel.kaufmann@umontreal.ca.
Andrés FinziCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2BA, Canada. Electronic address: andres.finzi@umontreal.ca.
Funding
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6MNovel HIV-1 Env trimer probes for efficient isolation of broadly neutralizing antibodiesR01AI122953 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WU, XUELING · 2016 to 2019
$2.6MNIAID NIH HHS R01 AI122953NIAID NIH HHS UM1 AI144462
Abstract
While the standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses administered 3 weeks apart, some public health authorities are spacing these doses, raising concerns about efficacy. However, data indicate that a single dose can be up to 90% effective starting 14 days post-administration. To assess the mechanisms contributing to protection, we analyzed humoral and T cell responses three weeks after a single BNT162b2 dose. We observed weak neutralizing activity elicited in SARS-CoV-2 naive individuals but strong anti-receptor binding domain and spike antibodies with Fc-mediated effector functions and cellular CD4
Indexed as
AdultAntibodies, NeutralizingAntibodies, ViralBetacoronavirusBNT162 VaccineCarrier ProteinsCOVID-19COVID-19 VaccinesFemaleHumansImmunityImmunoglobulin Fc FragmentsMaleMiddle AgedmRNA VaccinesSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineCarrier ProteinsCOVID-19 VaccinesImmunoglobulin Fc FragmentsmRNA VaccinesVaccines, SyntheticADCCcoronavirusCOVID-19humoral responsesmRNA vaccineneutralizationSARS-CoV-2spike glycoproteinsT cell responsesvariants
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.